Nasdaq

AstraZeneca Hypertension Drug Baxdrostat Wins FDA Priority Review

(RTTNews) - AstraZeneca's (AZN) New Drug Application (NDA) for experimental hypertension drug baxdrostat has been granted Priority Review by the U.S. Food and Drug Administration. The FDA has set a ...

Game-Changing Blood Pressure Drug Works for Patients Not Controlled by Standard Treatments

Researchers have found that a long-acting injection, given just twice a year alongside standard drugs. Blood pressure is one of the most common health problems worldwide, yet it remains difficult to ...
Labroots

New Drug for Treatment-resistant High Blood Pressure

New drug, baxdrostat, significantly lowered high blood pressure in patients resistant to standard treatments in a phase III clinical trial. The corresponding study was published in the New England ...
Morningstar

Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

AstraZeneca’s New Drug Application (NDA) for baxdrostat has been accepted for Priority Review by the US Food and Drug Administration (FDA) in the US for the treatment of adult patients with ...